Johnson & Johnson
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Johnson & Johnson's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $94 of operating cash. Lower than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$94Over the last 3 years, every $100 of reported profit came with $94 of operating cash.
Lower than 87% of Healthcare companies in United States.
Self-Funding Ratio
4.4×Over the last 3 years its own operating cash covered its investment spending (capex) 4.4 times.
Higher than 84% of Healthcare companies in United States.
Cash Locked Ratio
$24For every $100 of sales, $24 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $19 tied up three years earlier.
Less money tied up than 51% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$62Sales grew 18% in 3 years; of every extra $100 of sales, $62 became extra profit.
Higher than 74% of Healthcare companies in United States.
Asset Productivity Ratio
+18% / +6%In 3 years sales changed by +18% while total assets changed by +6%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
2.9×Debt due within a year is covered 2.9 times by its yearly operating cash.
Higher than 77% of Healthcare companies in United States.
Cash Cushion Ratio
−4%Debt, after subtracting cash, equals 4% of its market value (net debt).
Lower than 73% of Healthcare companies in United States.
Tangible Assets Ratio
50%Of every $100 the company owns, $50 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 80% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 79% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Johnson & Johnson owes $0.58 for every $1 it owns. Net profit rose 91% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
40.6Investors pay $40.6 for every $1 of Johnson & Johnson's yearly profit, higher than 74% of Healthcare companies in United States.
P/B ratio
7.59The share price is 7.59 times Johnson & Johnson's book value per share, higher than 82% of Healthcare companies in United States.
Market cap
$644.9 BThe total market value of all of Johnson & Johnson's shares at today's price (share price × number of shares), larger than almost all Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$85.0 BWhat Johnson & Johnson would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$35.26Net worth divided by the number of shares. The share price of $267.61 is 7.6 times this, which is the P/B above.
Owes vs Owns
0.58×Johnson & Johnson owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Dividend yield
2.08%Johnson & Johnson pays 2.08% of its share price as dividends a year, higher than 71% of dividend-paying Healthcare companies in United States.
Revenue growth
+6%Revenue rose 6% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Profit growth
+91%Net profit rose 91% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Profit margin
28.5%Johnson & Johnson keeps $28 of every $100 of revenue as net profit.
Cash quality
0.92×Cash from Johnson & Johnson's business was 0.92× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Interest cover
26.4×Johnson & Johnson's operating profit covered its interest costs 26.4 times in the year to Dec 2025.
Cash vs debt
Net debtJohnson & Johnson had $27.8 B more debt than cash (net debt) at Dec 2025.
Questions
What is Johnson & Johnson's P/E ratio?
Investors pay $40.6 for every $1 of Johnson & Johnson's yearly profit, higher than 74% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Johnson & Johnson: $644.9 B ÷ $85.0 B (30 Jun 2026) = 7.6.
How much does Johnson & Johnson owe compared with what it owns?
Johnson & Johnson owes $0.58 for every $1 it owns (moderate), higher than 62% of Healthcare companies in United States.
Does Johnson & Johnson pay a dividend?
Yes. Johnson & Johnson pays 2.08% of its share price as dividends a year, higher than 71% of dividend-paying Healthcare companies in United States.
Is Johnson & Johnson's revenue growing?
Revenue rose 6% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.